UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

Journal of clinical pharmacology, 2008-08, Vol.48 (8), p.919-925

2008

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

The Lancet (British edition), 2003-05, Vol.361 (9369), p.1597-1602

2003

Link zum Volltext

Verfügbarkeit prüfen

Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects

Malaria journal, 2010-09, Vol.9 (1), p.253-253, Article 253

2010

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)

Cancer chemotherapy and pharmacology, 2022-07, Vol.90 (1), p.19-27

2022

Link zum Volltext

Verfügbarkeit prüfen

Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen

Journal of clinical pharmacology, 2008-04, Vol.48 (4), p.428-435

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia

Journal of clinical pharmacology, 2003-06, Vol.43 (6), p.565-572

2003

Link zum Volltext

Verfügbarkeit prüfen

Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach

British journal of clinical pharmacology, 2013-12, Vol.76 (6), p.868-879

2013

Link zum Volltext

Verfügbarkeit prüfen

Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Cancer chemotherapy and pharmacology, 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks

International journal of clinical pharmacology and therapeutics, 2008-02, Vol.46 (2), p.102

2008

Link zum Volltext

Verfügbarkeit prüfen

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood, 2021-11, Vol.138 (Supplement 1), p.1283-1283

2021

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Cancer chemotherapy and pharmacology, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia

Journal of clinical pharmacology, 2003-06, Vol.43 (6), p.565-572

2003

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

Haematologica (Roma), 2006-07, Vol.91 (7), p.873

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state

Drug metabolism and disposition, 2010-05, Vol.38 (5), p.808

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects

European journal of drug metabolism and pharmacokinetics, 2016-12, Vol.41 (6), p.723-731

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers

International journal of clinical pharmacology and therapeutics, 2014-05, Vol.52 (5), p.369

2014

Link zum Volltext

Verfügbarkeit prüfen

Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study

International journal of clinical pharmacology and therapeutics, 2014-09, Vol.52 (9), p.739

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major

Haematologica (Roma), 2006-10, Vol.91 (10), p.1343

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects

International journal of clinical pharmacology and therapeutics, 2017-02, Vol.55 (2), p.147

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium

International journal of clinical pharmacology and therapeutics, 2013-10, Vol.51 (10), p.771

2013

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients

International journal of clinical pharmacology and therapeutics, 2016-06, Vol.54 (6), p.405

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)

International journal of clinical pharmacology and therapeutics, 2012-02, Vol.50 (2), p.118

2012

Link zum Volltext

Verfügbarkeit prüfen

Deferasirox does not induce QT/QTc-prolongation in healthy subjects

International journal of clinical pharmacology and therapeutics, 2009-05, Vol.47 (5), p.321

2009

Link zum Volltext

Verfügbarkeit prüfen

Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome

Gastroenterology (New York, N.Y. 1943), 2000-04, Vol.118 (4), p.A1160-A1160

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Humans
(25)
Male
(21)
Pharmacology & Pharmacy
(19)
Adult
(18)
Female
(17)
Area Under Curve
(15)
Pharmacokinetics
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Middle Aged
(11)
Adolescent
(10)
Cross-Over Studies
(9)
Pharmacology. Drug Treatments
(9)
Benzoates - Pharmacokinetics
(8)
Glycopyrrolate - Pharmacokinetics
(8)
Triazoles - Pharmacokinetics
(8)
Deferasirox
(7)
Iron Chelating Agents - Pharmacokinetics
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects

Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)

Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen

Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia

Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach

Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state

Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects

Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers

Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major

Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects

Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium

Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients

Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)

Deferasirox does not induce QT/QTc-prolongation in healthy subjects

Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome

Suchergebnisse filtern